ライフサイエンスコーパス: breast biopsy

1 lpable breast lesions is needle localization breast biopsy.

2 383 lesions) were referred for stereotactic breast biopsy.

3 ollowed within 6 months by benign excisional breast biopsy.

4 Breast adipose tissue was collected during breast biopsy.

5 n is removed at directional, vacuum-assisted breast biopsy.

6 erences of the value on avoiding any form of breast biopsy.

7 e for oncoprotein-related signaling in human breast biopsy.

8 a benign pathology result from image-guided breast biopsy.

9 (mean age, 48.5 years +/- 8.7) scheduled for breast biopsy.

10 breast cancer; 17% of the women had a prior breast biopsy.

11 breast tomosynthesis-guided vacuum-assisted breast biopsy.

12 ily history of breast cancer, and history of breast biopsy.

13 y be able to improve the PPV of image-guided breast biopsy.

14 or use in magnetic resonance vacuum-assisted breast biopsy.

15 , should be obtained with 14-gauge US-guided breast biopsy.

16 ethod for performing PEM-guided stereotactic breast biopsies.

17 mics has the potential to reduce unnecessary breast biopsies.

18 d from women scheduled to undergo diagnostic breast biopsies.

19 ergy mammography to limit unnecessary benign breast biopsies.

20 e patients had undergone previous excisional breast biopsies.

21 nce in determining the efficacy of MR-guided breast biopsies.

22 eterozygosity (HRD-LOH) in pretreatment core breast biopsies.

23 l and malignant tissues from human colon and breast biopsies.

24 CF-7 breast cancer cells as well as in human breast biopsies.

25 ased the number of their recommendations for breast biopsies.

26 ember 2011 and May 2014 from test sets of 60 breast biopsies (240 total cases, 1 slide per case), inc

27 268 surgical excisional and 796 percutaneous breast biopsies (290 US-guided, 370 stereotactically gui

28 One hundred twelve women awaited breast biopsy; 42, hepatic chemoembolization for cancer;

29 Results A total of 1313 women underwent 1405 breast biopsies: 643 by using DM (August 2013 to July 20

30 history of breast cancer (5%-8%), history of breast biopsy (7%-12%), and screening interval (2.1%-2.3

31 drink per day (975 [53%]), or having a prior breast biopsy (867 [48%]).

32 (adjusted OR, 1.07 [CI, 1.06 to 1.09]), and breast biopsy (adjusted OR, 1.10 [CI, 1.08 to 1.12]).

33 was performed in women scheduled to undergo breast biopsy after institutional review board approval

34 mixed effects models adjusted for history of breast biopsy, age, RefFreeCellMix cell estimates, time

35 ation in breast milk related with history of breast biopsy, an established risk factor for breast can

36 However, serial breast biopsy analysis in nonpregnant premenopausal wome

37 riple assessment without DBT resulted in 571 breast biopsies and enabled detection of 142 cancers.

38 US is routinely used to guide breast biopsies and is also emerging as a supplemental s

39 and race-matched 1:2 to women with a benign breast biopsy and calcifications visible on prior mammog

40 h percutaneous gastrostomy, mammography with breast biopsy and excision, and prostate biopsy with pro

41 e the optimal "base case" risk threshold for breast biopsy and perform sensitivity analysis.

42 r ultrasound-guided, large-core percutaneous breast biopsy and the evolution of mammotomy, radiologis

43 e optimal general threshold for image guided breast biopsy and the sensitivity of this threshold to v

44 scriptions of the advantages of percutaneous breast biopsy and the techniques of performing breast in

45 esonance (MR) imaging-guided vacuum-assisted breast biopsy and to explore the imaging, demographic, a

46 tumors, when compared with benign and normal breast biopsies, and a relationship to lymph node invasi

47 history of breast cancer, number of previous breast biopsies, and percentage density (PD).

48 ng included family history, race, age, prior breast biopsy, and breast density.

49 diagnostic mammographic work-up, breast US, breast biopsy, and clinical follow-up were retrospective

50 ss index (>25 vs 18.5-25), history of benign breast biopsy, and nulliparity or age at first birth (>/

51 y (body mass index >25.0), history of benign breast biopsy, and screening interval (biennial vs annua

52 non-SLN removed, tumor palpability, type of breast biopsy, and SLN injection technique were not sign

53 y of breast cancer, breast density, previous breast biopsy, and time since last mammogram; neighborho

54 amily history of breast cancer or a previous breast biopsy; and all women aged 40 to 79 years with bo

55 Currently, 80% of open breast biopsies are benign, resulting in excessive econo

56 umber of nonpalpable abnormalities requiring breast biopsy are being identified due to the widespread

57 Most women undergoing breast biopsy are found not to have cancer.

58 Metallic clips placed during core-needle breast biopsy are intended to mark the biopsy site when

59 A total of 141 patients who underwent breast biopsy at our institution between January 2010 an

60 family history of breast cancer, history of breast biopsy, BBD diagnoses, and breast density in the

61 st cancer, breast density, history of benign breast biopsy, BMI, and age at first live birth for inva

62 Readability of associated terms breast biopsy, breast cancer, and breast surgery was als

63 entirely account for differences in time to breast biopsy, but unmeasured factors, such as systemic

64 ty at color Doppler US with that of standard breast biopsy clips and radioactive seeds by using B-mod

65 Background For image-guided core-needle breast biopsy (CNBB), it remains unclear whether antithr

66 sed to acquire volumetric PAT and ultrasound breast biopsy datasets using 1100 nm light to identify h

67 ultrasound imaging system for use in making breast biopsy decisions prompted considerable interest i

68 Women with benign breast biopsies demonstrating both HER-2/neu amplificati

69 per case, 92.3% (95% CI, 91.4% to 93.1%) of breast biopsy diagnoses would be verified by reference c

70 disease (BBD) comprises approximately 75% of breast biopsy diagnoses.

71 cer status was ascertained on the basis of a breast biopsy done within 15 months after study entry or

72 ve screening mammogram that led to 19 benign breast biopsies, eight refused work-up, and three experi

73 n such cases, magnetic resonance (MR)-guided breast biopsy emerges as a crucial tool for accurate his

74 3 mammograms and 354 246 confirmatory tests (breast biopsies) every year, while screening the oldest

75 of a woman's age, breast density, history of breast biopsy, family history of breast cancer, and beli

76 A core needle breast biopsy finding of ADH for nonpalpable lesions the

77 an spectroscopy for guidance of stereotactic breast biopsies for microcalcifications are also discuss

78 th breast cancer who underwent contralateral breast biopsy for clinically or mammographically detecte

79 eness of hematoma-directed ultrasound-guided breast biopsy for nonpalpable lesions seen by magnetic r

80 reveals that 2% is the optimal threshold for breast biopsy for patients between 42 and 75 however the

81 tably, proliferation was markedly reduced in breast biopsies from BRCA1-mutation carriers who were tr

82 rived from them--obtained ex vivo from fresh breast biopsies from patients undergoing stereotactic br

83 907 patients scheduled for MR imaging-guided breast biopsy from 2004 to 2008.

84 Information on the terms breast biopsy (grade level readability score, 10.9), bre

85 ean PSS, IES, and CES-D scores, but only the breast biopsy group had highly abnormal anxiety levels.

86 breast tomosynthesis-guided vacuum-assisted breast biopsy has a higher rate of technical success tha

87 er, findings from clinical studies, in which breast biopsies have been taken or breast tissue density

88 ity, family history of breast cancer, benign breast biopsy history, breast density, body mass index,

89 justment variables were age, breast density, breast biopsy history, personal and family history of br

90 n's experience with image-guided core-needle breast biopsy (IGCNBB) and compare the pathologic result

91 From diagnosed breast biopsy images from two hospitals, we obtained 392

92 Study of pathologists who interpret breast biopsies in clinical practices in 8 US states.

93 ng may have potentially obviated unnecessary breast biopsies in six of eight lesions (P = .031).

94 the extent of lobule regression on a benign breast biopsy in 85 patients who developed breast cancer

95 uary 28, 2010, women undergoing percutaneous breast biopsy in an academic medical center were recruit

96 l threshold of breast cancer risk to perform breast biopsy in order to maximize a patient's total qua

97 reotactic coring excisional biopsy (Advanced Breast Biopsy Instrument [ABBI]), and wire-localized bio

98 Stereotactic core needle breast biopsy is a reproducible and reliable alternative

99 o these data, US-guided vacuum-assisted core breast biopsy is accurate.

100 Mammography following stereotactic breast biopsy is important to document the location and

101 ered suspicious signs of breast cancer and a breast biopsy is required, however, cancer is diagnosed

102 Stereotactic core-needle breast biopsy is widely used to obtain tissue for defini

103 n Readability of current online resources on breast biopsy lesions traditionally requiring surgery ma

104 tract, quantify, and topologically visualize breast biopsy lipid, stroma, hemoglobin, and nuclei dist

105 color Doppler US twinkling artifact of some breast biopsy markers in in vitro gel phantoms and in ex

106 Breast biopsy markers play an essential role in the surg

107 There is a clinically unmet need to make breast biopsy markers, particularly in the axilla, more

108 ts suggest that gene expression profiling of breast biopsies may become a valuable method for adequat

109 lts of this retrospective study suggest that breast biopsy may be avoided in women with palpable abno

110 ntithrombotic medications before core-needle breast biopsy may be unnecessary.

111 S-D score did not differ significantly among breast biopsy (mean score, 15; 95% CI: 13, 17), hepatic

112 Minimally invasive breast biopsy (MIBB) rates remain well below guideline r

113 Keywords: Breast Biopsy, Molecular Breast Imaging, Image-guided Bi

114 MRI examinations performed prior to breast biopsy; MRI results were interpreted at each site

115 mammary epithelial cells (n = 2) and benign breast biopsies (n = 21), BC cell lines (n = 7) and mali

116 n = 21), BC cell lines (n = 7) and malignant breast biopsies (n = 25) showed increased expression of

117 000 resynthesized ssODNs stratified healthy, breast biopsy-negative, and -positive women.

118 Although the breast biopsies on CEE were less commonly diagnosed as c

119 to identify women older than 66 years with a breast biopsy (open or minimally invasive) and subsequen

120 3 or 4 breast density and either a previous breast biopsy or a family history of breast cancer.

121 OR], 2.09; 95% CI, 1.92-2.28), postdiagnosis breast biopsies (OR, 1.74; 95% CI, 1.57-1.93), postdiagn

122 .001), education (OR, 1.22; P = .01), prior breast biopsy (OR, 2.16; P < .001), and residing in Conn

123 in volumetric breast density over time, and breast biopsy pathology-confirmed cancer.

124 Breast biopsy patients had a significantly higher mean S

125 PSS ratings of breast biopsy patients were significantly higher (mean s

126 with a mean score of 26 (95% CI: 23, 29) for breast biopsy patients, 23 (95% CI: 18, 28) for hepatic

127 centres, exploring the results of MR-guided breast biopsies performed by experienced radiologists, b

128 Results of 111 consecutive image-guided breast biopsies performed for microcalcifications deemed

129 otactic and ultrasonographically guided core breast biopsies performed from 2001 to 2005 were analyze

130 lence of occult breast carcinoma in surgical breast biopsies performed on nonpalpable breast lesions

131 ay facilitate histopathologic diagnosis from breast biopsies performed with imaging guidance.

132 term quality of life related to percutaneous breast biopsy procedures.

133 tional, vacuum-assisted and automated needle breast biopsies produced no distortion or suspicious int

134 table histopathologic result of percutaneous breast biopsy, provided that careful radiologic-histopat

135 sis of prospectively collected data, monthly breast biopsy recommendations after mammography, US, or

136 Purpose To examine breast biopsy recommendations and breast cancers diagnos

137 ptember 2020, there were substantially fewer breast biopsy recommendations with cancer diagnoses when

138 d, traditionally used as a level above which breast biopsy recommended, has been generalized to all p

139 mily history of breast cancer and a previous breast biopsy, regardless of breast density.

140 Breast biopsy reports were reviewed.

141 tic resonance imaging (MRI) and image-guided breast biopsy represent a few of multimodal visual strea

142 short-interval follow-up recommendations or breast biopsies, respectively.

143 ly history of breast cancer; previous benign breast biopsy result; high breast density; and, for youn

144 adiologic-pathologic-concordant percutaneous breast biopsy results could return to annual screening.

145 arison was made with mammographically guided breast biopsy results in 1,294 patients without breast c

146 ammography images and digital histopathology breast biopsy samples from benchmark datasets namely MIA

147 Fifty-eight frozen breast biopsy samples were used for these investigations

148 Prior breast biopsy, second-degree relatives with breast cance

149 125I-labeled VIP bound with high affinity to breast biopsy sections.

150 MR-guided breast biopsy serves as a remarkable tool for verifying

151 nalysis, based on interpretation of a single breast biopsy slide per case, predicts a low likelihood

152 gnostic interpretation was based on a single breast biopsy slide, overall agreement between the indiv

153 Thus, the finding of ADH in a core needle breast biopsy specimen actually may represent a sample o

154 s study, 473 microcalcifications detected on breast biopsy specimens from 56 patients were characteri

155 We reviewed benign breast-biopsy specimens from 1396 women enrolled in the

156 and increasing availability of MR-compatible breast biopsy systems, MRI of the breast is rapidly gain

157 Widespread acceptance of percutaneous breast biopsy techniques represents the most important p

158 s, thereby reducing the number of excisional breast biopsies that are performed.

159 tory of breast cancer, and history of benign breast biopsy), the estimated population attributable fr

160 In 495 stereotactic breast biopsies, the mammographic appearance of the biop

161 g-guided 9-gauge vacuum-assisted core-needle breast biopsy to be a reasonable alternative to MR imagi

162 t tomosynthesis (DBT)-guided vacuum-assisted breast biopsy (VABB) with that of prone stereotactic (PS

163 HER-2/neu amplification in benign breast biopsies was associated with an increased risk of

164 The rate of breast biopsies was not lower in the risk-based group (r

165 MR imaging-guided breast biopsy was canceled due to lesion nonvisualizatio

166 Prior breast biopsy was more strongly associated with the risk

167 ions; 14-gauge, directional, vacuum-assisted breast biopsy was performed in 40 lesions.

168 women (aged 32-98 years) undergoing BSGI and breast biopsy was performed.

169 Breast biopsies were based on clinical findings.

170 Breast biopsies were more frequent in the CEE group (cum

171 Pathology medical records on breast biopsies were obtained for the participants, and

172 In vivo breast biopsies were performed with the freehand techniq

173 Results from 1,400 consecutive core-needle breast biopsies were reviewed.

174 49 years; range, 26-70 years) scheduled for breast biopsy were included.

175 Conclusion There were substantially fewer breast biopsies with cancer diagnoses during the COVID-1

176 US-guided, vacuum-assisted breast biopsy with an 11-gauge device was performed in 7

177 ere found between SIFU and RTAS after benign breast biopsy with no significant differences in stage,

178 logic results with wire-localized excisional breast biopsy (WLEBB) for patients with positive cores a